VRTXVertex Pharmaceuticals Incorporated

$125B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$858M+34.0% YoY

Gross Profit

$763M88.9% margin

Operating Income

$277M32.2% margin

Net Income

$269M31.3% margin

EPS (Diluted)

$1.03

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$325M

Free Cash Flow

$307M

Stock-Based Comp.

$94M

Balance Sheet

Total Assets

$6.5B

Total Liabilities

$1.8B

Stockholders' Equity

$4.7B

Cash & Equivalents

$2.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$858M	$641M	+34.0%
Gross Profit	$763M	$569M	+34.1%
Operating Income	$277M	$129M	+114.7%
Net Income	$269M	$210M	+27.8%

Revenue Segments

SYMDEKO/SYMKEVI

$320M37%

ORKAMBI

$293M34%

KALYDECO

$244M28%

Geographic Segments

UNITED STATES

$641M62%

Non-US

$217M21%

Europe

$168M16%

VRTX Q1 2019 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena